期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

甲氨蝶呤治疗耐CD25单抗的重度胃肠型移植物抗宿主病初探 被引量：2

原文传递
导出
摘要 急性重度移植物抗宿主病（GVHD）是异基因造血干细胞移植（HSCT）后危及生命的重要合并症之一，累及肠道者死亡率高。目前治疗的一线药物为糖皮质激素，有效率40％～50％。无效者应用包括抗CD25单抗在内的二线药物治疗有效率为60％左右，仍有少数患者耐药。我们首次应用小剂量甲氨蝶呤（MTX）治疗单倍体HSCT后激素和CD25单抗耐药的急性重度胃肠型GVHD取得较好效果，现报道如下。
作者 赵婷 黄晓军 陈育红 许兰平 刘开彦 刘代红
机构地区 北京大学人民医院、北京大学血液病研究所
出处 《中华血液学杂志》 CAS CSCD 北大核心 2009年第7期489-490,共2页 Chinese Journal of Hematology
基金 基金项目：教育部2007年度创新团队发展计划（IRT0702）
关键词 重度移植物抗宿主病 抗CD25单抗 甲氨蝶呤治疗 胃肠型 异基因造血干细胞移植 糖皮质激素 治疗有效率 急性重度
分类号 R686 [医药卫生—骨科学]
  • 相关文献

参考文献10

  • 1Huang X J,Liu DH,Liu KY,et al.Haploidentieal hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies.Bone Marrow Transplant,2006,38:291-297.
  • 2Rowlings PA,Przepiorka D,Klein JP,et al.IBMTR severity index for grading acute GVHD:retrospective comparison with Glucksberg grade.Br J Haematol,1997,97:855-864.
  • 3抗癌药急性及亚急性毒性反应和分度标准(WHO标准)[J].癌症,1992,7:2-2.
  • 4MacMillan ML,Weisdorf DJ,Wagner JE,et al.Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease:comparison of grading systems.Biol Blood Marrow Transt plant,2002,8:387 -394.
  • 5Nelson JC,Benny JC.Prophylaxis and treatment of acute graftversus host disease.Semin Hematol,2006,43:32-41.
  • 6王景枝,刘开彦,许兰平,刘代红,陈育红,黄晓军.嵌合型CD25单抗治疗造血干细胞移植术后急性移植物抗宿主病[J].中华内科杂志,2008,47(11):923-925. 被引量：7
  • 7Hakan G,Ibrshim CH,Nelson JC.Acute grsft-vs-hest disease:puthobiology and management.Exp Hematol,2001,29:259-277.
  • 8Paul AC,Frederick RA,Lawrence C,et al.A humanized nonFcR-binding anti-CD3 antibody,visilizumab,for treatment of steroid-refractory acute graft-versus-best disease.Blood,2002,99:2712-2719.
  • 9Couriel D,Saliba R,Hicks K,et al.Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.Blood,2004,104:649-654.
  • 10Huang XJ,Jiang Q,Chen H,et al.Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoielic stem cell transplantation.Bone Marrow Transplant,2005,36:343 -348.

二级参考文献13

  • 1许兰平,黄晓军,刘开彦,陈欢,刘代红,张耀臣,陈育红,韩伟,高志勇,陆道培.异基因造血干细胞移植治疗Ph^+急性淋巴细胞白血病[J].北京大学学报（医学版）,2005,37(3):231-235. 被引量：13
  • 2Willenbacher W, Basara N, Blau IW, et al. Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab. Br J Haematol, 2001, 112:820-823.
  • 3Anasetti C, Hansen JA, Waldmann TA, et al. Treatment of acute graft-versus-host disease with humanized anti-Tat:an antibody that binds to the interleukin-2 receptor. Blood, 1994, 84 : 1320-1327.
  • 4Przepiorka D, Keman NA, Ippoliti C, et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood, 2000, 95:83- 89.
  • 5Perales MA, Ishill N, Eomazow WA, et al. Long-term follow-up of patients treated with daclizumab for steroid-refractoryacute graft- vs-host disease. Bone Marrow Transplant,2007,40:481-486.
  • 6Bordigoni P, Dimicoli S, Clement L, et al. Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease. Br J Haematol, 2006,135:382-385.
  • 7Schmidt-Hieber M, Fietz T, Knauf W, et al. Efficacy of the interleukino2 receptor antagonist basiliximab insteroid-refractory acute graft-versus-host disease. Br J Haematol, 2005, 130: 568- 574.
  • 8Weisdorf D, Haake R, Blazar B, et al. Treatment of moderate/ severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood, 1990, 75: 1024-1030.
  • 9Binder M, Vogtle FN, Michelfelder S, et al. Identification of their epitope reveals the structural basis for the mechanism of action of the immunosuppressive antibodies basiliximab and daclizumab. Cancer Res ,2007,67:3518-3523.
  • 10Webster AC, Playford EG, Higgins G, et al. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation, 2004,77 : 166-176.

共引文献6

同被引文献14

引证文献2

中华血液学杂志
2009年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部